Equity Profile

SRPT

Sarepta Therapeutics, Inc.

Health CareBiotechnology$1.9B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly genetic disorders like Duchenne muscular dystrophy (DMD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is crucial for understanding the company's profitability and growth potential, especially after recent surprises.

N/A

Revenue Growth

Revenue figures will indicate how well Sarepta is expanding its market presence and the success of its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

SRPT Q2-2026 Earnings Preview

Context

Company Snapshot

Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly genetic disorders like Duchenne muscular dystrophy (DMD). With a market cap of $2 billion, its advancements in gene therapy are significant in the health care sector, especially as demand for specialized treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+1856.93%

Avg Stock Reaction

-2.62%

Last Quarter Recap

In Q1-2026, Sarepta reported an impressive EPS of $3.16, significantly beating expectations. The stock reacted positively, gaining 5.69% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent strong performance. However, uncertainty remains due to the lack of guidance and analyst estimates.

Bull Case

If Sarepta continues its trend of beating EPS estimates, it could signal strong demand for its therapies and lead to a positive stock reaction.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to last quarter's $3.16?

Given the significant surprise last quarter, investors will be keen to see if this trend continues or if it was a one-time event.

What is the company's outlook on revenue growth for its therapies?

Revenue growth is critical for assessing the company's market position and future potential, especially in a competitive biotech landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Sarepta's therapies to capture a larger share of the rare disease market, especially given the recent positive EPS surprises.

Supporting Evidence

Sarepta has consistently beaten EPS estimates, indicating stronger performance than expected.

The options market is pricing in a relatively modest move, suggesting that significant upside potential may be overlooked.

Key Risk

If the EPS comes in above $3.50, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will either reinforce the positive momentum or raise doubts about the company's future.

Bull Confirmed If

An EPS of $3.50 or higher would confirm the bullish sentiment and indicate strong demand for its therapies.

Bear Confirmed If

An EPS below $2.00 would likely confirm bearish concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±4.61%

Historical Avg

±5.3%

In line with history

The options market is pricing in a moderate move, suggesting investors are anticipating some volatility around the earnings announcement.

Options are pricing ±4.6% while SRPT has averaged ±5.3% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.7%

30d HV

50.4%

Calls (88K)P/C Ratio: 0.27Puts (54K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sarepta beats expectations, history suggests a potential stock increase of around 0.82%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the news.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of around 12.94%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of new therapies in the pipeline.
2Management's commentary on market demand for existing products.
3Insights into competitive pressures in the biotechnology sector.
4Details on any strategic partnerships or collaborations.
5Future guidance on revenue growth expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly genetic disorders like Duchenne muscular dystrophy (DMD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is crucial for understanding the company's profitability and growth potential, especially after recent surprises.

N/A

Revenue Growth

Revenue figures will indicate how well Sarepta is expanding its market presence and the success of its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

SRPT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+1856.93%

Avg Stock Reaction

-2.62%

Last Quarter Recap

In Q1-2026, Sarepta reported an impressive EPS of $3.16, significantly beating expectations. The stock reacted positively, gaining 5.69% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent strong performance. However, uncertainty remains due to the lack of guidance and analyst estimates.

Bull Case

If Sarepta continues its trend of beating EPS estimates, it could signal strong demand for its therapies and lead to a positive stock reaction.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to last quarter's $3.16?

Given the significant surprise last quarter, investors will be keen to see if this trend continues or if it was a one-time event.

What is the company's outlook on revenue growth for its therapies?

Revenue growth is critical for assessing the company's market position and future potential, especially in a competitive biotech landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Sarepta's therapies to capture a larger share of the rare disease market, especially given the recent positive EPS surprises.

Supporting Evidence

Sarepta has consistently beaten EPS estimates, indicating stronger performance than expected.

The options market is pricing in a relatively modest move, suggesting that significant upside potential may be overlooked.

Key Risk

If the EPS comes in above $3.50, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will either reinforce the positive momentum or raise doubts about the company's future.

Bull Confirmed If

An EPS of $3.50 or higher would confirm the bullish sentiment and indicate strong demand for its therapies.

Bear Confirmed If

An EPS below $2.00 would likely confirm bearish concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±4.61%

Historical Avg

±5.3%

In line with history

The options market is pricing in a moderate move, suggesting investors are anticipating some volatility around the earnings announcement.

Options are pricing ±4.6% while SRPT has averaged ±5.3% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.7%

30d HV

50.4%

Calls (88K)P/C Ratio: 0.27Puts (54K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sarepta beats expectations, history suggests a potential stock increase of around 0.82%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the news.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of around 12.94%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of new therapies in the pipeline.
2Management's commentary on market demand for existing products.
3Insights into competitive pressures in the biotechnology sector.
4Details on any strategic partnerships or collaborations.
5Future guidance on revenue growth expectations.